# Cizzle Biotechnology acquisition of royalty deal in inflammatory pulmonary and cardiovascular diseases

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-acquisition-of-royalty-deal-in-inflammatory-pulmonary-and-cardiovascular-diseases/4121052647
- Published: 2022-02-14T07:20:08+00:00
- Author: Giles

**Cizzle Biotechnology Holdings plc** (LON:CIZ), the UK based diagnostics developer,
is pleased to announce that it has entered into a definitive agreement with Conduit
Pharmaceuticals Limited and St George Street Capital Limited to acquire a 5% economic
interest in the commercialisation of the AZD 1656 asset or other such assets being
developed by Conduit or SGSC to treat inflammatory pulmonary and cardiovascular 
disease.

**Highlights**

·    Agreement with Conduit and SGSC to acquire a 5% economic interest for a total
consideration of £1.88 million, to be settled in new Cizzle ordinary shares at a
price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February
2022

·    The Agreement is in addition to the Company’s existing interest in AZD 1656
as announced on 20 September 2021

·    SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical
trial in Covid-19 and SGSC and Conduit are in discussions with multiple pharmaceutical
companies about licensing opportunities for AZD 1656 for Covid-19 and potentially
for further indications

·    The Agreement supports the Company’s ambitions to expand its target customer
base into the pharmaceutical industry and is in line with its strategy of building
a portfolio of early cancer detection tests, companion diagnostics and royalty bearing
stakes in significant drug assets

> **Allan Syms, Executive Chairman of Cizzle Biotechnology, said**
> “The agreement announced today represents an important extension to our close 
> relationship with SGSC and Conduit. On 20 September 2021 we announced we had acquired
> a stake in SGSC’s AZD 1656 asset, providing the opportunity for the Company to
> receive royalty payments of up to £5 million and shortly after SGSC contracted
> the Company to develop an associated companion diagnostic test for which we will
> receive fees of up to £1 million.
> “We are now pleased to have the opportunity to increase our stake by an additional
> 5% in AZD 1656, but significantly the Economic Interest will be uncapped.  This
> new Agreement supports the Company’s ambitions to expand its target customer base
> in the pharmaceutical industry and through a strategy of building a portfolio 
> of early cancer detection tests, companion diagnostics and royalty bearing stakes
> in significant drug assets significantly increase shareholder value.” 

**Background**

SGSC is a UK-based medical-charity led by a group of highly decorated academics 
and ex-pharma executives formed to deliver much needed treatments to patients. SGSC’s
strategy is to take clinical-ready assets from pharmaceutical companies and to progress
them through Phase II medical trials, before licensing them on for Phase III trials
and commercialisation in order to create a return for investors and the charity 
alike. SGSC recently reported the successful completion of the AZD 1656 ARCADIA 
clinical trial in Covid-19 and SGSC and Conduit are in discussion with multiple 
pharmaceutical companies about licensing opportunities for AZD 1656 in both Covid-
19 and potentially in further indications. Conduit is the exclusive funding partner
to the Charity.

The ARCADIA trial data, that treated inflammatory pulmonary and cardiovascular disease
caused by Covid-19, showed a strong trend towards reduced mortality in patients 
receiving AZD 1656. The strong trend to improved mortality for patients on AZD 1656
was observed on top of patients receiving other medication as part of standard of
care. AZD 1656 was also shown to be well-tolerated in this patient population with
no serious adverse reactions (SARs) occurring. Overall, no safety concerns were 
identified regarding the use of AZD 1656 in this patient population.

Furthermore, SGSC has shown there was a significant increase in the migration of
the Regulatory T Cells (“Tregs”) from the patients who had taken the drug compared
to the Tregs from the patients who had not. Tregs are a specialised subpopulation
of T cells that act to suppress immune response and combat damaging cells, potentially
reducing serious cardiovascular and lung diseases which are causative in the development
of lung cancer, which Cizzle is developing its diagnostic test to identify.

Under the Agreement Cizzle Biotechnology will receive 5% of all such sums received
by SGS pursuant to any AstraZeneca (“AZ”) commercialisation or sub-license commercialisation
of the AZ asset in inflammatory pulmonary and cardiovascular diseases, after the
deduction of certain sums.

**Consideration for the Agreement**

Under the terms of the Agreement, Cizzle will pay consideration of £1.88 million
to SGS for the Economic Interest. Of the consideration payable, £1.0 million (the“
Initial Consideration”) will be satisfied by the issue of 25,000,000 new ordinary
shares in the Company (the “Consideration Shares”), at a price of 4.0 pence per 
Consideration Share, being a premium of 56.9 per cent. to the Company’s closing 
mid-market price of 2.55 pence on 11 February 2022. The remaining consideration 
of £880,000 will be payable in new ordinary shares in the Company issued at 4.0 
pence per share, on the sooner of receiving shareholder approval to issue the shares
or the first anniversary of completion.

**Total Voting Rights**

On completion of payment of the Initial Consideration, Conduit will hold 25,000,000
ordinary shares in Cizzle representing 8.98 per cent. of the issued share capital
of the Company, as enlarged by the issue of the Consideration Shares.

The Company has applied for admission of the 25,000,000 Initial Consideration new
Ordinary Shares to trading on the Standard Segment of the Official List and the 
Main Market of the London Stock Exchange (“Admission”).  It is expected that Admission
will become effective on or around 17 February 2022.

The Company’s issued ordinary share capital on Admission will consist of 278,447,788
ordinary shares of 0.1 pence each, all with voting rights. The Company holds no 
ordinary shares in Treasury. This figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company under the FCA’s
Disclosure Guidance and Transparency Rules.

Share on:
